Lineage Cell Therapeutics, Inc. (LCTX) stock forecast and price target
Price $0.91 · data as of November 13, 2026
12-month price target
Average target$5.50
Upside / downside+501.4%
Analysts6
ConsensusStrong buy
Low $3.00Average $5.50High $9.00
Gold marker: average target · white marker: today’s price ($0.91)
Analyst ratings
Strong buy 1Buy 5Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.09 | +58.5% | $6M |
| Next fiscal year ends December 31, 2027 | $-0.11 | −22.2% | $21M |
| Next quarter ends December 31, 2026 | $-0.04 | +0.0% | $1M |
| Quarter after ends March 31, 2027 | $-0.03 | — | $2M |
Consensus of the analysts covering Lineage Cell Therapeutics, updated daily.
Frequently asked questions
What is the Lineage Cell Therapeutics stock price target?
The average 12-month target from 6 analysts is $5.50, 501.4% above the current price of $0.91 Targets range from $3.00 to $9.00.
Is Lineage Cell Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 5 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Lineage Cell Therapeutics expected to earn?
Analysts expect EPS of $-0.09 for the fiscal year ending December 31, 2026 and $-0.11 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.